Anvisa allows Ypê factory to resume production in Amparo

Anvisa authorized the resumption of activities at the Ypê factory in Amparo on Friday after an inspection confirmed corrections. Products from lot ending in 1 remain suspended.

The National Health Surveillance Agency authorized the immediate resumption of operations at Química Amparo, the manufacturer of Ypê products, at the factory located in Amparo, São Paulo. The decision followed a joint reinspection with state and municipal agencies that verified the adequacy of corrective actions implemented by the company.

Anvisa president Leandro Safatle stated that the factory meets conditions to operate safely. He visited the site on Friday, May 29, 2026, alongside director Daniel Meirelles.

Liquid products with lot numbers ending in 1, manufactured before April 1, 2026, remain banned due to contamination by Pseudomonas aeruginosa. The company must submit laboratory reports for possible future release.

The initial suspension occurred in early May after an inspection identified quality control failures at the unit.

Relaterede artikler

Anvisa officials reviewing Ypê detergent products for potential suspension, with concerned consumers nearby.
Billede genereret af AI

Anvisa to rule this Wednesday on Ypê product suspension

Rapporteret af AI Billede genereret af AI

Anvisa will rule this Wednesday (13) on a Ypê appeal that could reinstate the suspension of the brand's detergents, liquid laundry detergents and disinfectants. The measure affects lots ending in 1 made in Amparo (SP). Meanwhile, consumers seek guidance on refunds or exchanges.

Ypê filed an appeal against an Anvisa decision that suspended manufacturing and ordered the recall of products. The measure was automatically suspended until judgment by the agency's board.

Rapporteret af AI

Ypê has decided to continue offering exchanges or refunds to consumers who prefer to return products from the final batch 1, even after Anvisa ruled that the items do not need to be recalled immediately.

Fiocruz has completed the technology transfer for dolutegravir, the main antiretroviral used in HIV treatment by Brazil's SUS. Large-scale production now depends on ANVISA registration.

Rapporteret af AI

The Food and Drug Supervisory Agency has revoked distribution permits for 11 cosmetic products found to contain hazardous and prohibited substances following inspections in the first quarter of 2026.

Dette websted bruger cookies

Vi bruger cookies til analyse for at forbedre vores side. Læs vores privatlivspolitik for mere information.
Afvis